---
schema_version: "secwatch.filing_event.v1"
accession: "0001818331-22-000075"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T21:00:51.181637+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sema4 exits reproductive health, cuts 500 jobs; Q3 net loss $77.6M, focuses on pediatric/rare disease

## Summary
- Exits reproductive/women's health testing; will close Stamford lab by Q1 2023, eliminate ~500 positions (32.5% of workforce).
- Q3 total revenue $83.2M (up from $43.2M YoY due to GeneDx); net loss $77.6M; adjusted net loss $76.8M.
- Pediatric/rare disease volumes up 20% YoY (pro forma); revenue growth >50%; adjusted gross margin >40% in that segment.
- Full-year 2022 guidance maintained: revenue $245-255M, adjusted gross margin 4-9%; aims to turn profitable by 2025.
- Appointed Kevin Feeley as CFO; total cash $205.7M as of Sep 30, 2022; shares outstanding 386.8M.

## SEC filing metadata
- accession: 0001818331-22-000075
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000181833122000075/0001818331-22-000075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000181833122000075/smfr-20221111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818331-22-000075
- JSON: https://secwatch.observer/filing/0001818331-22-000075.json
- Plain text: https://secwatch.observer/filing/0001818331-22-000075.txt

## Key facts
- Earnings Releases
  GeneDx Holdings Corp. reported Third Quarter 2022 results: revenue $83.2 million, net income ($77.6) million.
  - Period: Third Quarter 2022
  - Revenue: $83.2 million
  - Net income: ($77.6) million
  - Result: reported results
  source text: Total revenue for the third quarter of 2022 was $83.2 million compared to $43.2 million in the third quarter of 2021. Pro forma revenue in the third quarter of 2022, assuming GeneDx’s results were included for the full applicable quarter, excluding COVID-19 related revenue, was up 21%. Gross margin in the third quarter of 2022 was 16%. Adjusted gross margin in the third quarter of 2022 was 20%, with the pediatric and rare disease franchise generating an adjusted gross margin in excess of 40% in the quarter. Net loss in the third quarter of 2022 was ($77.6) million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818331/000181833122000075/0001818331-22-000075-index.htm
- Earnings Releases
  GeneDx Holdings Corp. updated its Full Year 2022 guidance (reaffirmed).
  - Period: Full Year 2022
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Full Year 2022 Guidance Sema4 is maintaining the previously
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818331/000181833122000075/0001818331-22-000075-index.htm
- Restructurings & Charges
  GeneDx Holdings Corp. announced a restructuring affecting reproductive and women’s health testing business (carrier screening, noninvasive prenatal, and other ancillary reproductive testing offerings) (approximately 500 positions, representing approximately 32.5% of its workforce).
  - Type: restructuring
  - Affected area: reproductive and women’s health testing business (carrier screening, noninvasive prenatal, and other ancillary reproductive testing offerings)
  - Headcount: approximately 500 positions, representing approximately 32.5% of its workforce
  source text: On November 14, 2022, the Company announced its plan to pursue a new strategic direction focused on the Company’s pediatric and rare disease testing business coupled with the Company's Centrellis data platform. As part of the Company’s strategic realignment, on November 11, 2022, the board of directors of the Company unanimously approved the Company’s exit from the reproductive and women’s health testing business, which includes carrier screening, noninvasive prenatal, and other ancillary reproductive testing offerings (the "RH Business"). Prior to the decision to exit the RH Business, the Company performed a thorough review of a number of factors including the competitive landscape, recent shifts in payor coverage and reimbursement, declining average selling prices, and cost structure, and consideration of existing capital markets constraints and the macroeconomic climate, and concluded that the RH Business is currently unsustainable and cannot be restructured in way that will allow t
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818331/000181833122000075/0001818331-22-000075-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.